首页> 外文期刊>Journal of Medicinal Chemistry >Scaffold Hybrid of the Natural Product Tanshinone I with Piperidine for the Discovery of a Potent NLRP3 Inflammasome Inhibitor
【24h】

Scaffold Hybrid of the Natural Product Tanshinone I with Piperidine for the Discovery of a Potent NLRP3 Inflammasome Inhibitor

机译:天然产物丹参酮I与哌啶的支架杂交,用于发现有效的NLRP3炎症小体抑制剂

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Natural products provide inspiration and have proven to be the most valuable source for drug discovery. Herein, we report a scaffold hybrid strategy of Tanshinone I for the discovery of NLRP3 inflammasome inhibitors. 36 compounds were designed and synthesized, and the cheminformatic analyses showed that these compounds occupy a unique chemical space. The biological evaluation identified compounds 5j, 12a, and 12d as NLRP3 inflammasome inhibitors with significant potency, selectivity, and drug-likeness. Mechanistic studies revealed that these Tanshinone I derivatives could inhibit the degradation of the protein NLRP3 and block the oligomerization of NLRP3-induced apoptosis-associated speck-like proteins, thus inhibiting NLRP3 inflammasome activation. In addition, the water solubility, in vitro metabolic stability, and oral bioavailability of these compounds were also greatly improved compared to Tanshinone I. Therefore, this protocol provides a new structural evolution of Tanshinone I and a new class of potent NLRP3 inflammasome inhibitors.
机译:天然产物提供灵感,并已被证明是药物发现最有价值的来源。在此,我们报道了丹参酮I用于发现NLRP3炎症小体抑制剂的支架杂交策略。设计合成了36种化合物,化学信息学分析表明,这些化合物占据了独特的化学空间。生物学评估确定化合物 5j、12a 和 12d 为 NLRP3 炎症小体抑制剂,具有显着的效力、选择性和药物相似性。机理研究表明,这些丹参酮I衍生物可以抑制NLRP3蛋白的降解,阻断NLRP3诱导的细胞凋亡相关斑点样蛋白的寡聚化,从而抑制NLRP3炎症小体的激活。此外,与丹参酮I相比,这些化合物的水溶性、体外代谢稳定性和口服生物利用度也大大提高。因此,该协议提供了丹参酮I的新结构演变和一类新的强效NLRP3炎症小体抑制剂。

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号